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Abstract
Context—Decision aids (DAs) prepare patients to make decisions about healthcare options 
consistent with their preferences. Helping patients choose among available options for colorectal 
cancer (CRC) screening is important because rates are lower than screening for other cancers. This 
systematic review describes studies evaluating patient DAs for CRC screening in average-risk 
adults and their impact on knowledge, screening intentions, and uptake.
Evidence acquisition—Sources included Ovid MEDLINE, Elsevier EMBASE, EBSCO 
CINAHL Plus, Ovid PsycINFO through July 21, 2015, pertinent reference lists, and Cochrane 
review of patient DAs. Reviewers independently selected studies that quantitatively evaluated a 
DA compared to one or more conditions or within a pre–post evaluation. Using a standardized 
form, reviewers independently extracted study characteristics, interventions, comparators, and 
outcomes. Analysis was conducted in August 2015.
Evidence synthesis—Twenty-three articles representing 21 trials including 11,900 subjects 
were eligible. Patients exposed to a DA showed greater knowledge than those exposed to a control 
condition (mean difference [MD], 18.3 of 100; 95% CI=15.5, 21.1), were more likely to be 
interested in screening (pooled relative risk [RR], 1.5; 95% CI=1.2, 2.0), and more likely to be 
screened (pooled RR, 1.3; 95% CI=1.1, 1.4). DA patients had greater knowledge than patients 
Address correspondence to: Robert J. Volk, PhD, Department of Health Services Research, Unit 1444, The University of Texas MD 
Anderson Cancer Center, P.O. Box 301402, Houston TX 77030. bvolk@mdanderson.org. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
All authors contributed to the conceptualization of the study, data acquisition and methods, interpretation of the study findings, 
revision of the manuscript for critical content, and final approval of the manuscript. We thank Dr. Gary Deyter for careful review and 
editing of the manuscript.
No financial disclosures were reported by the authors of this paper.
HHS Public Access
Author manuscript
Am J Prev Med. Author manuscript; available in PMC 2017 November 01.
Published in final edited form as:
Am J Prev Med. 2016 November ; 51(5): 779–791. doi:10.1016/j.amepre.2016.06.022.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
receiving general CRC screening information (pooled MD, 19.3 of 100; 95% CI=14.7, 23.8); 
however, there were no significant differences in screening interest or behavior.
Conclusions—DAs improve knowledge and interest in screening, and lead to increased 
screening over no information, but their impact on screening is similar to general CRC screening 
information.
Context
Colorectal cancer (CRC) is the second leading cause of cancer death among men and 
women in the U.S.1 CRC incidence and mortality have been declining2 owing to screening 
and improvements in treatment. Many tests, including fecal occult blood testing (both 
guaiac- and immunochemical-based), flexible sigmoidoscopy, and colonoscopy, are 
recommended to screen for CRC.3–7 Despite these recommendations, screening rates for 
CRC (59.5%) are lower than other recommended cancer screening tests such as breast 
cancer (72.4%) and cervical cancer (82.9%).8
One of the underlying factors contributing to low screening rates is suboptimal decision 
making, including low rates of assessing patient preferences.9 Patients have strong 
preferences for the different CRC screening test attributes such as accuracy, frequency of 
testing, and required preparation,10–15 but health providers have difficulty correctly 
identifying those preferences.9 Health providers tend to recommend colonoscopy, although 
many patients prefer fecal testing for a variety of reasons.16,17 Several organizations discuss 
the importance of including patient preferences to increase screening rates for CRC5 and 
allow individuals to make an informed decision when choosing one of the screening 
options.2,18,19
One way to promote consideration of patient preferences and informed decision making for 
CRC screening is through the use of patient decision aids. Patient decision aids provide 
information about options, and help patients to construct, clarify, and communicate the 
personal values they associate with the different features of the options.20–22 The desired 
outcome is a preference-concordant, informed decision, resulting from a high-quality shared 
decision-making process.21,22
A high-quality shared decision-making process is a valued outcome independent of the 
impact of patient decision aids on actual screening uptake. Previous systematic reviews of 
decision aids used in RCTs indicate that, in general, compared with standard care, decision 
aids improve decision quality by improving knowledge, risk perceptions, match between 
values and choices, and patient–provider communication, and decrease decisional conflict 
and passive decision making.23 The impact of decision aids on screening behaviors is 
inconsistent, and varies by topic. The overall purpose of this review was to describe studies 
that evaluated decision aids for CRC screening and to determine the impact of these aids in 
average-risk adults. Specifically, the aim was to determine the effect of decision aids 
compared to control conditions or to general CRC screening information on CRC screening 
knowledge, screening intention or interest, and uptake.
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Evidence Acquisition
Using the Cochrane Handbook24 and Guide,25 a review protocol was developed to help 
facilitate the review and to finalize study eligibility, information sources, and data elements 
for abstraction. The protocol was registered online through NIH Research’s international 
prospective register of systematic reviews (CRD42013002826, www.crd.york.ac.uk/
PROSPERO).
A research librarian searched Ovid MEDLINE, Elsevier EMBASE, EBSCO CINAHL Plus, 
and Ovid PsycINFO from inception through July 21, 2015. The search strategy for Ovid 
MEDLINE is provided in Appendix A (available online). The search was not limited to 
English-only publications and conference proceedings were included in order to obtain a 
broad picture of all existing decision aids for CRC screening. Reference lists of pertinent 
reviews were manually searched, including the Cochrane review of decision aids for 
treatment and screening.23 For the final selection of studies, English publications and only 
published journal articles were included although the aids were not limited to English 
language.
Trained raters (at least two for each search) independently reviewed each record retrieved 
from the search to assess for eligibility. Raters were not blinded to author, journal, or 
funding source. Raters checked titles and abstracts to rate each record as “included,” 
“excluded,” or “not sure.” After screening titles and abstracts, raters reviewed full texts for 
all records marked as “included” and “not sure” to assess for final eligibility. Raters first 
reviewed discordant ratings, and then the research team reviewed any unresolved 
discrepancies and those records still marked as “not sure.” Included were studies where the 
decision point was whether or not to be screened (i.e., one screening option compared to no 
screening), to choose between two or more screening options, or whether or not to continue 
screening for CRC. The intervention evaluated in the study had to be a decision aid, defined 
as information provided about the pros and cons of at least two screening options (including 
no screening) that allows the user to consider trade-offs between options. Trials that 
compared a decision aid to one or more comparators (e.g., control condition, general CRC 
screening information, other aid) had to have at least a post-evaluation. Uncontrolled trials 
or those studies that compared outcomes with a within-subjects design had to report a pre–
post evaluation, that is, a comparison of outcomes measured before and after the patient 
viewed the decision aid.
Data Extraction and Synthesis
Two trained reviewers independently extracted data from each article using a standardized 
abstraction form and procedure developed by the Task Force on Community Preventive 
Services26 as a guideline. Reviewers were not blinded to author, journals, or funding source. 
Reviewers extracted study characteristics including:
1. study purpose, taken directly from the abstract or text;
2. study design, categorized into RCT, controlled trial, or uncontrolled trial 
(within-subjects assessment);
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3. country, the geographic location of the study;
4. setting, where the recruitment took place and where the intervention was 
conducted;
5. sampled population, including sample size, age requirements, and any 
unique characteristics; and
6. measured outcomes.
Reviewers extracted intervention and comparison characteristics including decision aid 
name, format, theory used in the development, presented screening options, description of 
the content, features, and implementation process. Reviewers described comparisons and 
then categorized comparisons into the following:
1. no information, usual care, or health education materials not related to 
CRC screening (e.g., safety belt use, health tips), or use of a pre-test, post-
test design;
2. general CRC screening information, interventions that provided the basics 
about CRC and screening options, but lacked an opportunity to compare 
risks and benefits regarding the tests; and
3. another decision aid, where a version of the decision aid or another 
decision aid was the comparison.
Data analysis was completed in August 2015. For the quantitative analysis, eligible studies 
assessed knowledge, screening interest or intention, or screening uptake. All study designs 
and comparators to the decision aid were included. Study authors were only contacted to 
obtain data for the quantitative analysis if the data needed were not reported in the study.
Knowledge was analyzed in two ways. First, adequacy of knowledge was considered using 
the study’s predefined degree of knowledge that was determined to be adequate in making 
an informed decision. Adequate knowledge was dichotomized as adequate or inadequate. 
Second, overall accuracy knowledge was considered, expressed as the percentage of correct 
responses to a knowledge measure assessed during the final assessment.
Screening interest or intention was included for those studies where responses could be 
dichotomized to intended to be screened or intended not to be screened. Screening uptake 
was defined as the completion of any test for CRC indicated by self-report, medical chart 
review, or claims review. Screening uptake was dichotomized as screened and not screened.
The two main comparisons were the decision aid versus a control condition and the decision 
aid versus general CRC screening information. Because some studies compared decision 
aids or made multiple comparisons, two additional comparisons were included: a detailed 
decision aid versus a simple decision aid, and a decision aid with more options versus fewer 
options. For some of the meta-analyses, the results from the detailed and simple decision 
aids were combined and compared to a control condition or general CRC screening 
information. Sample sizes were recalculated as reported elsewhere27 for those studies that 
used a cluster design and where the intraclass correlation coefficient was provided. To avoid 
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unit of analysis error (over-precise results), the sample sizes and events were reduced to its 
effective size by calculating the average cluster size in the trial and the design effect for the 
trial.
Pooled occurrences and relative risks (RRs) for dichotomous outcomes (i.e., adequate 
knowledge, screening intention/interest) were calculated. Pooled occurrence information can 
be used to report absolute event rates of the outcomes for decision aid patients versus 
controls. For pooled occurrences, the Freeman–Tukey arcsine transformation was used to 
stabilize variances and conducted a meta-analysis using inverse variance weights. Then, 
estimates and CI boundaries were back-transformed into proportions. Mean differences 
(MDs) were calculated for continuous measures. The proportion of accurate knowledge 
responses was transformed into a percentage as suggested by O’Connor et al.20,28 When 
SDs were not directly reported in the article, the study authors were contacted, or they were 
imputed from other measures of dispersion (95% CIs or p-values from t-tests), or the 
baseline measurement reported in the study was used instead.
A sensitivity analysis was performed to assess the robustness of the methods used to impute 
by excluding any trials with imputed SDs. Study heterogeneity was assessed using the I2 
statistic and subsequent chi-square test. Fixed-effect meta-analysis was used if the score was 
<40%, and random-effects if it was ≥40%.29 Meta-regression was performed to investigate if 
study characteristics could explain the observed heterogeneity. Among the variables tested 
as predictors of study heterogeneity were study design, quality, follow-up, and type of 
comparison used (control condition or general CRC screening information). Study quality 
was assessed using the study quality form from the Guide to Community Preventive 
Services.26 The risk of publication bias was assessed through funnel plots and an Egger 
regression test.30 When the regression slope significantly deviated from the vertical slope, 
this was considered significant potential for bias. Statistical analyses were performed using 
RevMan, version 5.0.22 and Stata, version 10. All statistical tests were two-sided and 
defined the cut off for statistical significance as a p-value <0.05.
This study was funded by the National Cancer Institute, Agency for Healthcare Research 
and Quality, American Cancer Society, and Cancer Prevention Research Institute of Texas. 
The funding sources had no role in the design, conduct, collection, management, analysis, or 
interpretation of the data or in the preparation, review, or approval of the manuscript. The 
content is the sole responsibility of the authors.
Evidence Synthesis
After removal of duplicate records, the search identified 762 unique records for review 
(Figure 1). A total of 97 full-text articles were assessed for eligibility, which resulted in 23 
studies representing 21 trials included in the qualitative synthesis. For the quantitative 
synthesis, 20 trials were eligible: seven for accurate knowledge (percentage correct), six for 
adequate knowledge, 13 for screening intention or interest, and 13 for screening uptake.
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Qualitative Synthesis
The 21 trials included a total of 11,900 participants (Appendix Table 1, available 
online).31–53 Fourteen of the trials were RCTs including two randomized at the group level. 
Four of the trials were non-RCTs including one group-level design. The remaining three 
trials were uncontrolled using a pre–post assessment.
Sixteen of the trials took place in the U.S., two in Australia, one in Germany, one in Canada, 
and one in the Netherlands. Fifteen trials recruited participants from a clinical setting; five 
trials recruited from community settings such as telephone marketing databases, senior 
centers, or registries; and one trial recruited from both types of settings. For the trials that 
recruited participants from a clinical setting, six had the participant view the decision aid at 
home.
The majority of the trials focused on average-risk adults aged 50–74 years. Two of the trials 
focused on older adults, with one focusing on adults aged ≥65 years50 and the other on 
adults aged ≥75 years.40 Three of the trials focused on specific populations, including 
individuals with low education,47 individuals with low SES,41 and Hispanic or Latino 
individuals with limited English proficiency.51
Thirteen different decision aids for CRC screening were evaluated in the trials (Appendix 
Table 2, available online). Seven of the studies evaluated a version of a video called 
“Communicating Health Options through Interactive Computer Education,” three studies 
evaluated the Foundation for Informed Medical Decision Making (now Informed Medical 
Decisions Foundation) video titled, “Colon Cancer Screening: Deciding What’s Right for 
You,” and 11 aids were developed by the study investigators. Video decision aids were in a 
variety of formats including VHS, DVD, computer-based, and web-based. Interactive 
programs were either computer- or web-based. For five studies, the main component of the 
decision aid was a printed booklet. There was a wide range of theories and frameworks used 
during development (Appendix Table 2, available online). Theory used in the development 
of the decision aid was not mentioned for four of the 13 aids.
Seven different screening options were presented in the decision aids. The most common 
option presented in the aids was fecal occult blood testing, presented as an option in all the 
decision aids except for a study that compared a colonoscopy decision aid and a CT-
colonography decision aid.31 The next most common screening option was colonoscopy, 
followed by flexible sigmoidoscopy, barium enema, a combination of flexible 
sigmoidoscopy and fecal occult blood test, and CT-colonography. Twelve of the studies 
evaluated decision aids that included no screening either explicitly as an option (e.g., no 
testing, wait and see) or presented it during trade-offs of test attributes, including all four 
non-U.S. studies.
Three of the studies used pre–post comparisons without a control group. For the controlled 
trials, eight of the trials compared a decision aid to a control condition that included no 
information about CRC screening (e.g., video about automobile or drug refill safety, handout 
on ways to stay healthy), and seven compared a decision aid to general CRC screening 
information with fewer details or less attractive presentation. Not enough information was 
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provided about the general CRC screening information to compare the content with the 
decision aid. In addition, seven trials compared it to another aid or another version of the aid. 
For example, one trial compared an aid with a no screening option to the aid without the 
option,34 one trial compared a five-option aid to a two-option version,35 and one trial 
compared a decision aid with and without a personalized risk calculator.45,46 For the 
controlled trials, three of the 21 trials had more than one comparison condition.45–47,50
Thirteen trials assessed knowledge (Appendix Table 1, available online).31,33–36,40,43,45–51 
Seven of the trials assessed interest in screening,34,35,37–39,47,50 and nine assessed intentions 
for screening.32–34,40,45,46,48–51 Several of the studies measured a variation of interest or 
intention, including attitudes toward screening (four trials),31,33,45–48 intentions to ask or 
discuss screening (four trials),33,37,38,51 and stage of readiness (five trials).36,37,41,42,44,53 
Fifteen of the trials assessed screening uptake or test completion,31,32,37–39,41–49,51–53 and 
seven assessed test preference.35,37,38,41,42,44–46,53 Several of the trials measured a variation 
of behavior or test preference, including if screening was discussed (four trials)33,42,45,46,51 
or if a test was ordered (four trials).37,41,42,45,46,53
Many of the studies measured the extent to which the decision aid improved informed 
decision making by using a combination of measured outcomes. For example, one study 
defined informed choice as a combination of adequate knowledge and clear values.49 Three 
other studies defined informed choice as adequate knowledge and attitude toward screening 
consistent with behavior.31,47,48
Meta-analysis Results
The pooled rates of adequate knowledge, screening interest or intention, and screening 
uptake are shown in Table 1. Nearly half of the patients exposed to any type of decision aid 
were deemed to have adequate knowledge (49%, 95% CI=36%, 62%). However, most 
studies considered adequate knowledge in a subjective fashion with cut offs specified by the 
authors. The pooled rates of screening interest or intention for patients in any type of 
decision aid group was 66% (95% CI=54%, 77%), but uptake was only 33% (95% CI=22%, 
46%). Patients in the general CRC screening information group showed lower rates of 
adequate knowledge, but similar screening interest/intention and screening uptake rates. 
Patients in a control condition group (e.g., usual care, no CRC screening information, other 
health information) had lower rates for all three outcomes.
All comparisons described in this section can be found in Table 2.
Accuracy of knowledge was reported as the proportion of correct responses (percentage 
correct) or adequate knowledge (threshold specified a priori by the authors). Patients in the 
decision aid group improved their knowledge compared with either those patients in a 
control condition or receiving general CRC screening information (MD=18.3%, 95% 
CI=15.5%, 21.2% and MD=19.3%, 95% CI=14.7%, 23.8%, respectively). Patients in the 
decision aid group were more likely to have adequate knowledge after the intervention 
compared with the group receiving general CRC screening information (RR=2.6, 95% 
CI=1.4, 5.1). There were no differences in knowledge between different versions of decision 
aids (detailed versus simple or more options versus fewer options).
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More patients in the decision aid group expressed interest or intention to undergo screening 
compared with those patients in a control condition (RR=1.5, 95% CI=1.2, 2.0). The 
absolute group benefit was 14% (95% CI=4%, 24%), that is, in the decision aid group, 40 of 
100 people reported interest in screening versus 26 of 100 for the control group. The number 
needed to treat was eight (95% CI=4, 21), interpreted as eight people had to be exposed to 
the decision aid in order for one additional person to report interest on being screened. 
Similar rates of screening interest or intention were observed in the patients assigned to the 
decision aid group compared to the general CRC screening information group (RR=1.1, 
95% CI=0.93, 1.3).
Patients in the decision aid group were 1.3 times more likely to complete screening at 16–52 
weeks compared with the patients in control conditions (e.g., usual care, no CRC screening 
information, other health information) (95% CI=1.1, 1.4). The absolute group benefit was 
8% (95% CI=6%, 11%), that is, in the decision aid group, 47 of 100 people completed their 
screening over 16–52 weeks, versus 40 of 100 for the control group. The number needed to 
treat was ten (95% CI=7, 25), interpreted as ten people had to be exposed to the decision aid 
in order for one additional person to get screened. No other statistically significant 
differences were observed.
When comparing rates of screening completion by follow-up time for patients receiving the 
decision aid versus those patients receiving only general CRC screening information, no 
differences were observed at 4, 8–12, or 24 weeks. No other associations were found 
between treatment effects and study design, quality, or follow-up. Publication bias was not 
observed.
Discussion
This review found that decision aids for CRC screening improve patients’ knowledge by 
about 20% compared with control conditions and general CRC screening information. This 
increase in knowledge is higher than the 13% difference reported in a Cochrane systematic 
review of decision aids for various healthcare conditions.21 Decision aids are associated with 
greater intentions to be screened and screening uptake compared to control conditions. 
However, compared to general CRC information, intentions and uptake are not statistically 
significant when decision aids are used.
It is important to not lose sight of the rationale for using of patient decision aids, that is, to 
improve the decision-making process and match between preferences and choices.21,22 
Similar to studies of decision aids in general, current evaluations of CRC screening decision 
aids are limited in their attention to the decision-making process. This review showed greater 
knowledge among patients receiving decision aids compared with standard CRC screening 
information, and knowledge is one key component of a high-quality decision.
The wide range of theories and frameworks used to guide development of the decision aids 
does not allow for a detailed examination of the impact of specific theories on patient 
outcomes. More research is needed to better understand how the theoretic underpinnings of 
decisions aids influence their effectiveness.54 Similarly, more research is needed to 
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determine which patient groups are most likely to benefit from decision support compared 
with general information about CRC screening. For example, the development, use, and 
evaluation of decision aids with lower-literacy populations is recommended.21 It is 
noteworthy that four of the trials in this review focused on vulnerable populations with 
mixed effects of the decision aid on screening uptake.41,45–47,51 Clearly, there is a need for 
more research on the role of patient decision aids on CRC screening decisions for vulnerable 
populations where the burden of CRC may be highest.
Decision making about screening for CRC is an interesting and challenging prevention 
model for decision aid developers. There is a both persuasive component and a preference-
sensitive component to the decision. In general, there is strong evidence from randomized 
trials and modeling studies supporting several different screening tests and schedules in 
decreasing CRC incidence and mortality.4 Although presenting a no-screening option to 
patients may be ethically justifiable and advocated in standards for decision aid 
developers,55 it can be argued that the net benefit of CRC screening warrants promotion of 
screening. This persuasive emphasis is in contrast to the question of which screening test is 
best for a given patient. Here, the evidence is equivocal, and a values-based decision is 
generally recognized as the desired outcome.
In this review, the tension between a persuasive emphasis (i.e., the decision to be tested) and 
preference sensitivity (i.e., which test to have) was reflected in the decision context selected 
by the researchers, and the choice of measured outcomes. When the focus of the decision 
was to choose between test options, shared decision making was encouraged in order to 
increase screening uptake. Primary outcomes measured included test preference, screening 
uptake, and concordance between preference and test completed. Of note, all of the studies 
where the decision was to choose between test options were conducted in the U.S., where 
preventive services recommendations strongly endorse CRC screening for eligible patients.4 
If the decision was whether to be screened or to continue screening, informed decision 
making was encouraged in order to promote informed choice. Here, the majority of the 
studies defined informed choice as having adequate knowledge and a match between values 
or attitude toward screening and screening behavior. Most of these studies were conducted 
outside the U.S., where CRC screening is not universally endorsed.
Limitations
There are several limitations to this systematic review. First, all study designs and study 
quality were included in the meta-analysis. Though this can influence findings, the 
sensitivity analysis indicated that the findings were robust across study design or quality. 
Second, a broad definition of a decision aid was used and no rating of the aids used in the 
trials against international standards for content, development, and evaluation of decision 
aids was conducted.55,56 Third, the outcomes in the meta-analysis were measured using a 
variety of scales. For example, studies were included that measured screening uptake in 
various ways—self-report, medical chart review, and medical claims review. Fourth, owing 
to the nature of the study, the review was constrained to the data published or provided by 
the authors. Finally, adequacy of patients’ knowledge was based on the authors’ a priori 
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criteria given there is no consensus on essential facts a patient should know to make an 
informed screening choice.
Conclusions
When compared with general CRC screening information, decision aids appear to lead to 
greater patient knowledge of CRC and screening options, while having a similar impact on 
screening rates. As part of a high-quality shared-decision making experience, decisions aids 
have value independent of their impact on screening rates. Further improvements in 
colorectal cancer screening rates may be achieved by aligning patient and provider 
preferences. Focused efforts to integrate patient decision aids in routine clinical practice57,58 
appear highly justified given the potential to favorably impact both patient cognitive 
outcomes and screening rates.
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Figure 1. 
Study flow for the systematic review of colorectal cancer screening decision aid studies.
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